Yale study unlocks secrets of heart failure drug entresto

NCT ID NCT04649229

Completed Knowledge-focused Sponsor: Yale University Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study looked at how the heart failure drug Entresto (LCZ696) lowers blood pressure and helps the body get rid of salt. 46 stable heart failure patients took part. Researchers measured blood pressure and urine sodium levels to understand the drug's effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Entresto (LCZ696)
What this could lead to: If successful, this could help doctors understand how Entresto works in the body to lower blood pressure and manage heart failure more effectively.
What could go wrong: This is a small, completed study focused on understanding mechanisms, not on proving a new treatment works. Results may not apply to all heart failure patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

heart failure systolic heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEART FAILURE

Contacts and locations

Locations

Yale New Haven Hospital

New Haven, Connecticut, 06520, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.